1887

Chapter 60 : Epstein-Barr Virus and Cytomegalovirus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Epstein-Barr Virus and Cytomegalovirus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH60-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH60-2.gif

Abstract:

Epstein-Barr virus (EBV; also known as human herpesvirus 4 [HHV-4]) and cytomegalovirus (CMV; also known as HHV-5) logically belong in the same chapter. Both of these human herpesviruses are major pathogens for the immunocompromised host, and both are capable of causing disease during primary infection, reactivation, or superinfection. They, along with BK polyomavirus, are the feared viral triumvirate that complicates hematopoietic cell transplantation (HCT) or solid organ transplantation. This chapter emphasizes recognition of EBV and CMV diseases and focuses on the clinical relevance of laboratory findings.

Citation: Balfour H, Hogquist K, Verghese P. 2016. Epstein-Barr Virus and Cytomegalovirus, p 563-577. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch60
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Correlations between time of primary infection, disease expression, immune responses, and viral loads.

Citation: Balfour H, Hogquist K, Verghese P. 2016. Epstein-Barr Virus and Cytomegalovirus, p 563-577. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch60
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch60
1. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702703.[CrossRef]
2. Henle G, Henle W, Diehl V. 1968. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 59:94101.[PubMed].[CrossRef]
3. Farrell PJ,. 2005. Epstein-Barr virus genome, p 263287. In Robertson ES (ed), Epstein-Barr Virus. Caister Academic Press, Norfolk, England.
4. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:40844092.[PubMed]
5. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. 2009. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 143:209221.[CrossRef].[PubMed]
6. Puchhammer-Stöckl E, Görzer I. 2006. Cytomegalovirus and Epstein-Barr virus subtypes—the search for clinical significance. J Clin Virol 36:239248.[CrossRef]
7. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. 2009. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 5:e1000496.[CrossRef].[PubMed]
8. Nemerow GR, Wolfert R, McNaughton ME, Cooper NR. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 55:347351.[PubMed]
9. Speck P, Haan KM, Longnecker R. 2000. Epstein-Barr virus entry into cells. Virology 277:15.[CrossRef].[PubMed]
10. Xiao J, Palefsky JM, Herrera R, Berline J, Tugizov SM. 2009. EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells. Virology 388:335343.[CrossRef].[PubMed]
11. Chesnokova LS, Nishimura SL, Hutt-Fletcher LM. 2009. Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci USA 106:2046420469.[CrossRef].[PubMed]
12. Tsurumi T, Fujita M, Kudoh A. 2005. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 15:315.[CrossRef].[PubMed]
13. Ambinder RF, Lin L. 2005. Mononucleosis in the laboratory. J Infect Dis 192:15031504.[CrossRef].[PubMed]
14. Henderson A, Ripley S, Heller M, Kieff E. 1983. Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci USA 80:19871991.[PubMed].[CrossRef]
15. Thorley-Lawson DA, Gross A. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:13281337.[CrossRef].[PubMed]
16. Laichalk LL, Thorley-Lawson DA. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79:12961307.[CrossRef].[PubMed]
17. Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. 2013. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 207:8088.[CrossRef].[PubMed]
18. Gerber P, Walsh JH, Rosenblum EN, Purcell RH. 1969. Association of EB-virus infection with the post-perfusion syndrome. Lancet i:593595.
19. Alfieri C, Tanner J, Carpentier L, Perpête C, Savoie A, Paradis K, Delage G, Joncas J. 1996. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 87:812817.[PubMed]
20. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RL, Najarian JS. 1981. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 41:42534261.[PubMed]
21. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS. 1999. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:15171525.[PubMed].[CrossRef]
22. Chang RS, Char DF, Jones JH, Halstead SB. 1979. Incidence of infectious mononucleosis at the Universities of California and Hawaii. J Infect Dis 140:479486.[PubMed].[CrossRef]
23. Dan R, Chang RS. 1990. A prospective study of primary Epstein-Barr virus infections among university students in Hong Kong. Am J Trop Med Hyg 42:380385.[PubMed]
24. de-Thé G, Day NE, Geser A, Lavoué MF, Ho JH, Simons MJ, Sohier R, Tukei P, Vonka V, Zavadova H. 1975. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study—a review. IARC Sci Publ 1975:316.
25. Lehane DE. 1970. A seroepidemiologic study of infectious mononucleosis. The development of EB virus antibody in a military population. JAMA 212:22402242.[PubMed].[CrossRef]
26. Balfour HH Jr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. 2013. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. J Infect Dis 208:12861293.[CrossRef].[PubMed]
27. Fafi-Kremer S, Morand P, Brion JP, Pavese P, Baccard M, Germi R, Genoulaz O, Nicod S, Jolivet M, Ruigrok RW, Stahl JP, Seigneurin JM. 2005. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J Infect Dis 191:985989.[CrossRef].[PubMed]
28. Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb CH, Cavert W, Wang DH, Brundage RC. 2005. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis 192:15051512.[CrossRef].[PubMed]
29. Hess RD. 2004. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol 42:33813387.[CrossRef].[PubMed]
30. Ginsburg CM, Henle W, Henle G, Horwitz CA. 1977. Infectious mononucleosis in children. Evaluation of Epstein-Barr virus-specific serological data. JAMA 237:781785.[PubMed].[CrossRef]
31. Horwitz CA, Henle W, Henle G, Goldfarb M, Kubic P, Gehrz RC, Balfour HH Jr, Fleisher GR, Krivit W. 1981. Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10–48 months). Blood 57:933938.[PubMed]
32. Sprunt TP, Evans FA. 1920. Mononuclear leucocytosis in reaction to acute infections (“infectious mononucleosis”). Johns Hopkins Hosp Bull 31:410417.
33. Hoagland RJ. 1952. Infectious mononucleosis. Am J Med 13:158171.[PubMed].[CrossRef]
34. Odumade OA, Hogquist KA, Balfour HH Jr. 2011. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 24:193209.[CrossRef].[PubMed]
35. Rea TD, Russo JE, Katon W, Ashley RL, Buchwald DS. 2001. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 14:234242.[PubMed]
36. Auwaerter PG. 1999. Infectious mononucleosis in middle age. JAMA 281:454459.[PubMed].[CrossRef]
37. Horwitz CA, Henle W, Henle G, Schapiro R, Borken S, Bundtzen R. 1983. Infectious mononucleosis in patients aged 40 to 72 years: report of 27 cases, including 3 without heterophil-antibody responses. Medicine (Baltimore) 62:256262.[PubMed].[CrossRef]
38. McKinlay CA. 1935. Infectious mononucleosis. Part I. Clinical aspects. JAMA 105:761764.[CrossRef]
39. Hoagland RJ. 1960. The clinical manifestations of infectious mononucleosis: a report of two hundred cases. Am J Med Sci 240:5563.[PubMed].[CrossRef]
40. Jenson HB. 2000. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr 12:263268.[PubMed].[CrossRef]
41. Robinson RG. 1988. Abdominal complications of infectious mononucleosis. J Am Board Fam Pract 1:207210.[PubMed]
42. Bell AT, Fortune B, Sheeler R. 2006. Clinical inquiries. What test is the best for diagnosing infectious mononucleosis? J Fam Pract 55:799802.[PubMed]
43. Paul JR, Bunnell WW. 1932. The presence of heterophile antibodies in infectious mononucleosis. Am J Med Sci 183:90103.[CrossRef]
44. Fisher BA, Bhalara S. 2004. False-positive result provided by rapid heterophile antibody test in a case of acute infection with hepatitis E virus. J Clin Microbiol 42:4411.[CrossRef].[PubMed]
45. Horwitz CA, Henle W, Henle G, Penn G, Hoffman N, Ward PC. 1979. Persistent falsely positive rapid tests for infectious mononucleosis. Report of five cases with four—six-year follow-up data. Am J Clin Pathol 72:807811.[PubMed].[CrossRef]
46. Blake JM, Edwards JM, Fletcher W, McSwiggan DA, Pereira MS. 1976. Measurement of heterophil antibody and antibodies to EB viral capsid antigen IgG and IgM in suspected cases of infectious mononucleosis. J Clin Pathol 29:841847.[PubMed].[CrossRef]
47. Downey H, McKinlay CA. 1923. Acute lymphadenosis compared with acute lymphatic leukemia. Arch Intern Med 32:82112.[CrossRef]
48. Odumade OA, Knight JA, Schmeling DO, Masopust D, Balfour HH Jr, Hogquist KA. 2012. Primary Epstein-Barr virus infection does not erode preexisting CD8+ T cell memory in humans. J Exp Med 209:471478.[CrossRef].[PubMed]
49. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. 2011. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17:11851193.[CrossRef].[PubMed]
50. Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, Maccario R, Fiocchi R, Gerna G. 2000. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 38:613619.[PubMed]
51. Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. 2008. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 80:441454.[CrossRef].[PubMed]
52. Hayden RT, Hokanson KM, Pounds SB, Bankowski MJ, Belzer SW, Carr J, Diorio D, Forman MS, Joshi Y, Hillyard D, Hodinka RL, Nikiforova MN, Romain CA, Stevenson J, Valsamakis A, Balfour HH Jr U S EBV Working Group. 2008. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol 46:157163.[CrossRef].[PubMed]
53. WHO International Laboratory Standards and Control. 2014. 1st WHO International Standard for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Techniques. NIBSC code 09/260. http://www.nibsc.org/documents/ifu/09-260.pdf.
54. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ. 2001. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98:972978.[PubMed].[CrossRef]
55. Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. 2003. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 41:52455249.[PubMed].[CrossRef]
56. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, Bucsky P. 2001. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72:10121019.[PubMed].[CrossRef]
57. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. 2001. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 3:7987.[PubMed].[CrossRef]
58. Stevens SJ, Pronk I, Middeldorp JM. 2001. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 39:12111216.[CrossRef].[PubMed]
59. Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr. 2012. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 26:741747.[CrossRef].[PubMed]
60. De Souza YG, Freese UK, Greenspan D, Greenspan JS. 1990. Diagnosis of Epstein-Barr virus infection in hairy leukoplakia by using nucleic acid hybridization and noninvasive techniques. J Clin Microbiol 28:27752778.[PubMed]
61. Resnick L, Herbst JS, Ablashi DV, Atherton S, Frank B, Rosen L, Horwitz SN. 1988. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 259:384388.[PubMed].[CrossRef]
62. Gulley ML. 2001. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 3:110.[CrossRef].[PubMed]
63. Gulley ML, Tang W. 2010. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 23:350366.[CrossRef].[PubMed]
64. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM. 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 31:185196.[CrossRef].[PubMed]
65. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi , Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM. 2006. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119:608614.[CrossRef].[PubMed]
66. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, Naoe T, Esaki S, Kikuta A, Sawada A, Kawa K, Ohshima K, Nakamura S. 2012. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119:673686.[CrossRef].[PubMed]
67. Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC. 2007. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 39:1621.[CrossRef].[PubMed]
68. Henles G, Henle W, Klein G. 1971. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer 8:272282.[CrossRef]
69. Wohlrabe P, Färber I, Wutzler P, Uhlig R. 1989. Antibodies to Epstein-Barr virus-induced early antigens in blood donors. Acta Virol 33:344348.[PubMed]
70. Li S, Deng Y, Li X, Chen QP, Liao XC, Qin X. 2010. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J 123:12011205.[PubMed]
71. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. 2004. Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 26:598602.[CrossRef].[PubMed]
72. Nikoskelainen J, Neel EU, Stevens DA. 1979. Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J Clin Microbiol 10:7579.[PubMed]
73. Bauer G. 2001. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab 47:223230.[PubMed]
74. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. 2009. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology 391:249256.[CrossRef].[PubMed]
75. Sims S, Willberg C, Klenerman P. 2010. MHC-peptide tetramers for the analysis of antigen-specific T cells. Expert Rev Vaccines 9:765774.[CrossRef].[PubMed]
76. Letsch A, Scheibenbogen C. 2003. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 31:143149.[PubMed].[CrossRef]
77. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587617.[CrossRef].[PubMed]
78. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. 2000. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood 95:241248.[PubMed]
79. Vogl BA, Fagin U, Nerbas L, Schlenke P, Lamprecht P, Jabs WJ. 2012. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation. J Med Virol 84:119131.[CrossRef].[PubMed]
80. Pender MP, Csurhes PA, Pfluger CM, Burrows SR. 2012. CD8+ T cells far predominate over CD4+ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. Blood 120:50855087.[CrossRef].[PubMed]
81. Macedo C, Webber SA, Donnenberg AD, Popescu I, Hua Y, Green M, Rowe D, Smith L, Brooks MM, Metes D. 2011. EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J Immunol 186:58545862.[CrossRef].[PubMed]
82. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB. 1998. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:13951402.[PubMed].[CrossRef]
83. Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, Abbott RJ, Sabbah S, Kwok W, Rickinson AB. 2013. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med 210:933949.[CrossRef].[PubMed]
84. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28:710722.[CrossRef].[PubMed]
85. Ryan JL, Fan H, Swinnen LJ, Schichman SA, Raab-Traub N, Covington M, Elmore S, Gulley ML. 2004. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 13:6168.[PubMed].[CrossRef]
86. Ribbert H. 1904. Ueber protozoenartige Zellen in der Niere eines syphilitischen Neugeborenen und in der Parotis von Kindern. Zentralbl Allg Pathol 15:945948.
87. Jesionek A, Kiolemenoglou B. 1904. Ueber einen Befund von protozoenartigen Gebilden in den Organen eines hereditar-luetischen Foetus. Munch Med Wochenschr 51:19051907.
88. Vonglahn WC, Pappenheimer AM. 1925. Intranuclear inclusions in visceral disease. Am J Pathol 1:445466.3.[PubMed]
89. Lipschuetz B. 1921. Untersuchungen ueber die Aetiologie der Krankheiten der Herpes genitalis. Arch Dermatol Syph 136:428482.[CrossRef]
90. Wyatt JP, Saxton J, Lee RS, Pinkerton H. 1950. Generalized cytomegalic inclusion disease. J Pediatr 36:271294.[PubMed].[CrossRef]
91. Fetterman GH. 1952. A new laboratory aid in the clinical diagnosis of inclusion disease of infancy. Am J Clin Pathol 22:424425.[PubMed].[CrossRef]
92. Minder WH. 1953. Die Atiologie der Cytomegalia infantium. Schweiz Med Wochenschr 83:11801182.[PubMed]
93. Enders JF, Weller TH, Robbins FC. 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:8587.[CrossRef].[PubMed]
94. Smith MG. 1956. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 92:424430.[PubMed].[CrossRef]
95. Rowe WP, Hartley JW, Waterman S, Turner HC, Huebner RJ. 1956. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med 92:418424.[PubMed].[CrossRef]
96. Craig JM, Macauley JC, Weller TH, Wirth P. 1957. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 94:412.[PubMed].[CrossRef]
97. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673685.[CrossRef].[PubMed]
98. Bancroft GJ, Shellam GR, Chalmer JE. 1981. Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance. J Immunol 126:988994.[PubMed]
99. Starr SE, Garrabrant T. 1981. Natural killing of cytomegalovirus-infected fibroblasts by human mononuclear leucocytes. Clin Exp Immunol 46:484492.[PubMed]
100. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ. 2008. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41:206212.[CrossRef].[PubMed]
101. Marshall EE, Geballe AP. 2009. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res 29:609619.[CrossRef].[PubMed]
102. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F. 2005. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:10311036.[CrossRef].[PubMed]
103. Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T. 2006. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 6:23562364.[CrossRef].[PubMed]
104. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. 2013. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21:21132121.[CrossRef].[PubMed]
105. Moss P. 2010. The emerging role of cytomegalovirus in driving immune senescence: a novel therapeutic opportunity for improving health in the elderly. Curr Opin Immunol 22:529534.[CrossRef].[PubMed]
106. Derhovanessian E, Maier AB, Hähnel K, Zelba H, de Craen AJ, Roelofs H, Slagboom EP, Westendorp RG, Pawelec G. 2013. Lower proportion of naive peripheral CD8+ T cells and an unopposed pro-inflammatory response to human cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr) 35:13871399.[CrossRef].[PubMed]
107. Limaye AP, Boeckh M. 2010. CMV in critically ill patients: pathogen or bystander? Rev Med Virol 20:372379.[CrossRef].[PubMed]
108. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. 2007. Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant 21:149158.[CrossRef].[PubMed]
109. Dollard SC, Grosse SD, Ross DS. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:355363.[CrossRef].[PubMed]
110. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253276.[CrossRef].[PubMed]
111. Iwasenko JM, Howard J, Arbuckle S, Graf N, Hall B, Craig ME, Rawlinson WD. 2011. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 203:15261533.[CrossRef].[PubMed]
112. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA. 2010. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21:15791586.[CrossRef].[PubMed]
113. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O Jr, Sarwal MM. 2007. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 11:187195.[CrossRef].[PubMed]
114. Courivaud C, Bamoulid J, Chalopin JM, Gaiffe E, Tiberghien P, Saas P, Ducloux D. 2013. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis 207:15691575.[CrossRef].[PubMed]
115. Scott GM, Naing Z, Pavlovic J, Iwasenko JM, Angus P, Jones R, Rawlinson WD. 2011. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients. J Clin Virol 51:229233.[CrossRef].[PubMed]
116. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:20322036.[CrossRef].[PubMed]
117. Razonable RR, Hayden RT. 2013. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev 26:703727.[CrossRef].[PubMed]
118. Kaden J, Zenker S, Eichler C, Groth J, May G, Strobelt V, Oesterwitz H, Scholz D, Lippert J, Adamczyk G. 1991. Risk of CMV infection and illness after kidney transplantation. Allerg Immunol (Leipz) 37:4758.
119. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E Valganciclovir Solid Organ Transplant Study Group. 2005. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R[minus] transplant recipients. Am J Transplant 5:10651070.[CrossRef].[PubMed]
120. Paya CV, Smith TF, Ludwig J, Hermans PE. 1989. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc 64:670675.[PubMed].[CrossRef]
121. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, Boyce CS, Sullivan LA, Southwick PC. 2010. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116:16551662.[CrossRef].[PubMed]
122. Egli A, Humar A, Kumar D. 2012. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 55:16781689.[CrossRef].[PubMed]
123. Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Würzner R, Schönitzer D, Grubeck-Loebenstein B. 2005. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 79:36753683.[CrossRef].[PubMed]
124. Derhovanessian E, Maier AB, Hähnel K, Beck R, de Craen AJ, Slagboom EP, Westendorp RG, Pawelec G. 2011. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol 92:27462756.[CrossRef].[PubMed]
125. Moins-Teisserenc H, Busson M, Scieux C, Bajzik V, Cayuela JM, Clave E, de Latour RP, Agbalika F, Ribaud P, Robin M, Rocha V, Gluckman E, Charron D, Socié G, Toubert A. 2008. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 198:818826.[CrossRef].[PubMed]
126. Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12:492499.[PubMed].[CrossRef]
127. La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP, Diamond DJ. 2008. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 197:2533.[CrossRef].[PubMed]
128. Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M. 2008. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 8:14861497.[CrossRef].[PubMed]
129. Dirks J, Egli A, Sester U, Sester M, Hirsch HH. 2013. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells. Transpl Infect Dis 15:7989.[CrossRef].[PubMed]
130. Dirks J, Tas H, Schmidt T, Kirsch S, Gartner BC, Sester U, Sester M. 2013. PD-1 analysis on CD28([minus]) CD27([minus]) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant 13:31323141.[CrossRef].[PubMed]
131. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A Transplantation Society International CMV Consensus Group. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333360.[CrossRef].[PubMed]
132. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Köhler H. 2001. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:12871294.[PubMed].[CrossRef]
133. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, Bell S, Gailbraith A, McNeil K, Jones S, Khanna R. 2007. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 9:165170.[CrossRef].[PubMed]
134. Westall G, Kotsimbos T, Brooks A. 2006. CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation. Am J Transplant 6:577584.[CrossRef].[PubMed]
135. Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, Crough T, Durrant ST, Morton JA, Butler JP, Misra AK, Hill GR, Khanna R. 2013. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 8:e74744.[CrossRef].[PubMed]
136. Król L, Stuchlý J, Hubáček P, Keslová P, Sedláček P, Starý J, Hrušák O, Kalina T. 2011. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant 46:10891098.[CrossRef]
137. Egli A, Humar A, Kumar D. 2012. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 55:16781689.[CrossRef].[PubMed]
138. Ravkov EV, Pavlov IY, Hanson KE, Delgado JC. 2012. Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplant. Clin Dev Immunol 2012:451059.[CrossRef].[PubMed]
139. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, Ghanekar SA, Maino VC, Delarosa C, Disis ML. 2008. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9:9.[CrossRef].[PubMed]
140. Borchers S, Bremm M, Lehrnbecher T, Dammann E, Pabst B, Wölk B, Esser R, Yildiz M, Eder M, Stadler M, Bader P, Martin H, Jarisch A, Schneider G, Klingebiel T, Ganser A, Weissinger EM, Koehl U. 2012. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 7:e50248.[CrossRef].[PubMed]
141. Abu-Khader A, Krause S. 2013. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation—a comparison of different assays for the detection of cytomegalovirus-specific T cells. Eur J Haematol 91:534545.[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Recommended laboratory tests for diagnosis and management of EBV infections

Citation: Balfour H, Hogquist K, Verghese P. 2016. Epstein-Barr Virus and Cytomegalovirus, p 563-577. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch60
Generic image for table
TABLE 2

EBV infection category according to patterns of EBV-specific antibody tests

Citation: Balfour H, Hogquist K, Verghese P. 2016. Epstein-Barr Virus and Cytomegalovirus, p 563-577. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch60
Generic image for table
TABLE 3

Laboratory tests for diagnosis and management of CMV infections

Citation: Balfour H, Hogquist K, Verghese P. 2016. Epstein-Barr Virus and Cytomegalovirus, p 563-577. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch60

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error